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Aims: To compare the time spent in specified glycaemic ranges in people with type 1 diabetes
(T1D) during 5 consecutive days of moderate-intensity exercise while on either 100% or 75% of
their usual insulin degludec (IDeg) dose.
Materials and Methods: Nine participants with T1D (four women, mean age 32.1  9.0 years,
body mass index 25.5  3.8 kg/m2, glycated haemoglobin 55  7 mmol/mol (7.2%  0.6%) on
IDeg were enrolled in the trial. Three days before the first exercise period, participants were
randomized to either 100% or 75% of their usual IDeg dose. Participants exercised on a cycle
ergometer for 55 minutes at a moderate intensity for 5 consecutive days. After a 4-week wash-
out period, participants performed the last exercise period for 5 consecutive days with the alter-
nate IDeg dose. Time spent in specified glycaemic ranges, area under the curve and numbers of
hypoglycaemic events were compared for the 5 days on each treatment allocation using a
paired Students' t test, Wilcoxon matched-pairs signed-rank test and two-way ANOVA.
Results: Time spent in euglycaemia over 5 days was greater for the 75% IDeg dose versus the
100% IDeg dose (4008  938 minutes vs. 3566  856 minutes; P = 0.04). Numbers of hypo-
glycaemic events (P = 0.91) and time spent in hypoglycaemia (P = 0.07) or hyperglycaemia
(P = 0.38) was similar for both dosing schemes.
Conclusions: A 25% reduction in usual IDeg dose around regular exercise led to more time spent
in euglycaemia, with small effects on time spent in hypo- and hyperglycaemia.
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1 | INTRODUCTION
Insulin degludec (IDeg) is associated with improved glycaemic control
(glycated haemoglobin [HbA1c] concentration), lower risk of
hypoglycaemia and less glycaemic variability compared with insulin
glargine (IGlar) because of its favourable pharmacokinetic and pharma-
codynamic properties.1–3 The risk of exercise-induced hypoglycaemia
during exercise and for the subsequent 24 hours is similar with IDeg
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and IGlar, despite different pharmacodynamic profiles and duration of
action.4
Various therapy strategies have been suggested to reduce the risk
of exercise-induced hypoglycaemia, namely, prandial bolus insulin
dose reductions, additional carbohydrate consumption and/or basal
insulin reductions.5 Therapy adjustment is mainly based on acute
exercise-specific factors, such as the intensity, duration and type of
exercise; however, other factors, such as circulating insulin concentra-
tions, hepatic and skeletal muscle glycogen storage and counterregu-
latory hormone concentrations need to be considered when
performing exercise. Patients on multiple daily injections are advised
to reduce pre- and post-exercise prandial bolus insulin dose by 25%
for low-intensity, 50% for moderate-intensity and 75% for high-
intensity exercise performed for 30 to 45 minutes.6 Blood glucose
levels between 7 mmol/L (126 mg/dL) and 10 mmol/L (180 mg/dL)
should be targeted by administering additional carbohydrates depend-
ing on the volume of exercise (eg, 15-20 g/h).6
An unaltered usual dose of IDeg can be employed safely as a
background insulin if patients wish to engage in low-, moderate- and
high-intensity exercise when applying bolus insulin dose reductions.7,8
The risk of hypoglycaemia of an acute bout of exercise may persist for
at least 24 hours, driven partly by circulating insulin levels and
increased tissue insulin sensitivity.5 Although basal rate reductions are
recommended in patients running on continuous subcutaneous insulin
infusion, limited data exist on basal insulin dose reductions for multi-
ple dose insulin injections.5,9 Campbell et al10 reported that reducing
the basal insulin dose combined with reduced prandial bolus insulin
dose protects the individual from hypoglycaemia for 24 hours after
moderate-intensity exercise. Importantly, these adjustments were not
associated with significant increases in time spent in hyperglycaemia
(67  16 minutes) or hypoglycaemia (5  6 minutes) within the
24 hours post-exercise period.
The vast majority of research investigating the safety of basal
insulins assessed only an acute bout of exercise.4,8,11 In line with
international guidelines, individuals with type 1 diabetes (T1D) are
recommended to exercise regularly as part of their usual care.9 This
raises the question of whether regular exercise exposes the patient to
a greater risk of hypoglycaemia as a result of the additive insulin-
sensitizing effects of these repeated exercise bouts.
Regular exercise is a cornerstone of good diabetes management
and more people with T1D are channelling their motivation to exer-
cise into attempting sport events such as marathon running, long dis-
tance cycling or triathlons.12,13 This commitment is accompanied by
regular training for many months, with acute exercise sessions often
performed over consecutive days. The same is also true for people
with T1D performing a week of irregular exercise, such as a skiing
week or an activity holiday.14 Considering the long-lasting effect of
IDeg,1–3 rapid changes in the circulating IDeg concentrations for iso-
lated exercise bouts are not possible; however, there is no research in
the literature that has explored the impact of IDeg dose reduction on
glycaemia when people with T1D are regularly exercising. Interest-
ingly, despite this lack of research, a recent review did not recommend
IDeg dose reductions around regular exercise because this might com-
promise overall glycaemic control.5 Nocturnal hypoglycaemia, a
potentially life-threatening event,15,16 occurs more frequently in
people with T1D after performing exercise compared with when daily
exercise was not performed because of the extended effect of exer-
cise.17 The incidence of developing post-exercise hypoglycaemia after
moderate-intensity exercise has been reported to be up to 66% in
individuals with T1D across studies.18,19 So far, no research has inves-
tigated the effect of basal insulin dose reductions on day- and night-
time glycaemia when patients are exercising regularly.
In the present study, we compared the time spent in specified gly-
caemic ranges during 5 consecutive days of continuous moderate-
intensity exercise, stratified for time of day as well as for first and last
period within the 5 days, either treated with 100% or 75% of their
usual IDeg dose in people with T1D.
2 | MATERIAL AND METHODS
2.1 | Study procedures
This single-centre, randomized, open-label, two-period, crossover trial
was performed in line with the Declaration of Helsinki and Good Clini-
cal Practice and was approved by the ethics committee of the Medical
University of Graz (29-334 ex 16/17) and local health authority
(EudraCT number: 2017-000922-37). The trial was registered at the
German Clinical Trials Register (DRKS.de; DRKS00013477).
2.2 | Screening visit
Adults (aged 18-65 years, both inclusive) with T1D (diagnosed >
12 months) eligible for this study had a body mass index of 18.5 to
32 kg/m2, an HbA1c concentration of 42 to 86 mmol/mol (6%-10%),
a fasting C-peptide level of < 0.25 nmol/L and were on multiple daily
injections. Participants were exercising >150 min/wk with moderate
intensity or > 75 min/wk with high intensity. People with diabetes-
related complications (micro- and macrovascular), women of child-
bearing potential, who were pregnant, breastfeeding, intending to
become pregnant or not using adequate contraceptive methods, peo-
ple with illness or disease that might confound the study results, peo-
ple receiving drugs that might interfere with insulin action, people
with suspected allergy to the trial products or addiction to alcohol or
drugs, and people with mental incapacity were excluded.
After assessment of eligibility, participants filled in the Interna-
tional Physical Activity Questionnaire to assess physical activity (MET
min/wk). They then performed an incremental cardiopulmonary exer-
cise test on a cycle ergometer until maximal volitional exhaustion,
defined as detected oxygen uptake (VO2) plateau, a maximum lactate
concentration > 10 mmol/L, a respiratory exchange ratio (RER) > 1.1
and inability to maintain a cadence ≥ 50 rpm for 5 seconds. Pulmonary
gas exchange variables were measured continuously during the incre-
mental cardiopulmonary exercise testing by breath-by-breath mea-
surement, and were averaged over 5 seconds (METAMAX® 3B;
Cortex Biophysik GmbH, Leipzig, Germany). Heart rate was measured
continuously via chest belt telemetry and was also averaged over
5 seconds (s810i, Polar Electro, Espoo, Finland). A 12-lead ECG and
blood pressure measurement were obtained for cardiovascular moni-
toring (ZAN 600; nSpire Health, Oberthulba, Germany). Capillary
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blood lactate and glucose concentration were taken from the earlobe
at rest, at the end of the warm-up phase, after each exercise step until
maximum voluntary exhaustion, at the end of the active recovery and
finally, at the end of the passive recovery (Biosen S-line, EKF Diagnos-
tics, Barleben, Germany).8 Additionally, blood glucose obtained from
fingertip was measured via blood glucometer (FreeStyle Libre, Maid-
enhead, UK) every 2 minutes to minimize the risk of hypoglycaemia.
At the beginning of the incremental cardiopulmonary exercise
test, participants sat on the cycle ergometer for 3 minutes (0 W)
before they started the warm-up period of 3 minutes by pedalling at a
workload of 20 W. Then, the workload increased by 10, 15 or 20 W
every minute, depending on their expected functional capacity to
reach a total test duration of 8 to 12 minutes. Finally, a 3-minute
active recovery at 20 W followed by 3 minutes' passive recovery
(0 W) were conducted. The first and second lactate points (LTP1 and
LTP2) as well as the maximum power output (Pmax) were determined
to prescribe the exercise intensity for the upcoming two exercise
periods.20–22 As participants were already on IDeg (Tresiba; Novo
Nordisk A/S, Bagsvaerd, Denmark), a stable basal insulin therapy was
defined as a pre-breakfast self-measured blood glucose concentration
of 4 to 7 mmol/L (72-126 mg/dL) over 6 days.
Additionally, participants received an unblinded intermittently
viewed continuous glucose monitoring (CGM) system (FreeStyle Libre)
and were trained on how to use the system. Participants inserted and
wore the sensor on the back of the upper arm without any over-
bandage for 14 days. If the sensor expired or fell off, participants
immediately inserted a new sensor on the back of the alternate upper
arm. Within the first 24-hour calibration period, participants per-
formed at least five additional blood glucose measurements via gluc-
ometer because of the system's inaccuracy during this run-in period.
Additionally, participants changed the sensor earlier if the sensor
would expire within the 5-day exercise period. Data were then
exported at the end of each dosing scheme and 15-minute averaged
data were used for the analyses. Seven participants were already
using the intermittently viewed CGM system prior to the start of the
study.
2.3 | Trial visits
Three days before the first exercise period, participants were random-
ized to either 100% or 75% of their usual IDeg dose, injected once-
daily in the evening. Randomization was performed using the web-
based randomization tool “Randomiser for Clinical Trials: http://www.
randomizer.at/” provided by the Institute of Medical Informatics, Sta-
tistics and Documentation, Medical University of Graz. Then partici-
pants exercised on a cycle ergometer for 55 minutes at a moderate
intensity (midpoint between LTP1 and LTP2 [63%  7% VO2max]) for
5 consecutive days in the evening (at 5:00 PM or 6:30 PM) at the clinical
research facility. In total, 90 days of continuous interstitial glucose
measurements were available (nine participants performed 10 exercise
sessions; five for each of the two dosing schemes). Participants were
instructed to avoid additional structured exercise during the days of
exercise procedures.
Prior to the exercise periods, participants consumed on average
3.4  0.3 g carbohydrates per body weight (kg) per day. Participants
were encouraged to consume 5 to 7 g carbohydrates per body weight
(kg) per day, beginning 1 day before the 5-day exercise period, and to
replicate their diet for both dosing schemes.23 All participants were
treated with IDeg as a basal insulin and insulin lispro (Eli Lilly,
Indianapolis, Indiana; n = 3) or insulin aspart (Novo Nordisk; n = 6) as
a bolus insulin. Prandial bolus insulin dose, correction bolus insulin
doses, basal insulin doses, prandial carbohydrates and correction car-
bohydrates were documented in a standardized diary, beginning 1 day
before the first exercise session. Participants were counting carbohy-
drates prior to the start of the trial and this was maintained during the
run of the trial. They were trained and experienced in carbohydrate-
counting, with annual refreshers. At each visit, diaries were reviewed
by the study team and a dietician was consulted if necessary. Prior to
the incremental cardiopulmonary exercise testing and the 5-day exer-
cise period, participants were told to inject the last bolus insulin and
consume the last pre-exercise carbohydrate-rich meal at least 2 hours
before exercise to minimize the impact of bolus insulin/meal-induced
blood glucose variability. If blood glucose concentration was
<7 mmol/L (126 mg/dL) 15 minutes before the exercise, 15 to 30 g
carbohydrates were given to the participants (fruit juice or glucose
gel); in contrast, when blood glucose concentration was >10 mmol/L
(180 mg/dL) carbohydrate administration was delayed until reaching
7 mmol/L (126 mg/dL).23 Administration of carbohydrates was
repeated if blood glucose concentration did not rise above 7 mmol/L
(126 mg/dL) within 10 minutes; however, when blood glucose con-
centration reached a hypoglycaemic threshold of 3.9 mmol/L (70 mg/
dL), exercise testing was discontinued until reaching 7 mmol/L
(126 mg/dL). During the continuous moderate-intensity exercise ses-
sions, pulmonary gas exchange variables and heart rate were collected
continuously, and capillary blood samples were taken from the ear
lobe at rest, at the end of the warm-up period, every 7 minutes during
the target workload, and at the end of the active and passive recovery
periods, to determine lactate concentrations. Additionally, glucose
concentrations were measured via blood glucose from fingertip and
via interstitial glucose from the intermittently viewed CGM system
every 7 minutes. Venous blood samples were taken from the antecu-
bital vein immediately before (M1, reference value) and immediately
after the first exercise session (M2), 23 hours after the first exercise
session (M3), immediately before (M4) and immediately after the last
exercise session (M5) as well as 23 hours after the last exercise ses-
sion (M6) to determine plasma insulin levels by chemiluminescence on
an ADVIA Centaur system (Siemens Healthcare Diagnostics,
Eschborn, Germany).
2.4 | Statistical analyses
The sample size was estimated using the calculator freely available at
http://www.sample-size.net, applying a paired Student's t test. For the
sample size estimation, we assumed a mean time in euglycaemia in the
full basal insulin dosing scheme (100% IDeg) of 643  54 min/d.10
Assuming a moderate and clinically relevant improvement of 10% of
mean time in euglycaemia in the reduced dosing scheme (75% IDeg),
10 participants were required for the study to detect this difference, with
an α value of 0.05 and a power of 0.90. Data for time spent in euglycae-
mia (4.0-9.9 mmol/L [71-179 mg/dL]), hypoglycaemia (≤3.9 mmol/L
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[≤70 mg/dL]), serious hypoglycaemia (≤2.9 mmol/L [≤53 mg/dL]), hyper-
glycaemia (≥10 mmol/L, [≥180 mg/dL]) and serious hyperglycaemia
(≥16.7 mmol/L [≥300 mg/dL]) were analysed for the period from post-
first-exercise session until 24 hours after the last exercise session for
comparing both dosing schemes (100% IDeg vs. 75% IDeg) excluding the
exercise sessions.24 For all glycaemic ranges the area under the curve
(AUC; eg, AUC euglycaemia = excluding hypo- and hyperglycaemia) was
calculated using the trapezoid method (sum of trapezoids
AUC¼ Concentration0+Concentration12 x Time1−Time0½ Þ and compared between
the dosing schemes. Additionally, glycaemic variability, defined as
coefficient of variation in glycaemic values, numbers of hypoglycaemic
episodes (interstitial glucose ≤ 3.9 mmol/L [70 mg/dL] for
≥15 minutes), dose of preprandial and correction bolus insulin doses
as well as prandial and hypoglycaemic correction carbohydrates were
compared between the dosing schemes. Interstitial glucose data
obtained from the intermittently viewed CGM system were averaged
over 15 minutes. Data were tested for distribution using the Shapiro–
Wilk normality test. Comparisons between dosing schemes were per-
formed via paired Student's t test, Wilcoxon matched-pairs signed-
rank test and two-way ANOVA with Bonferroni's multiple compari-
sons test (P < 0.05). Data were analysed with SPSS (version 22; SPSS
Inc, Chicago, Illinois) and Graphpad Prism (version 7; San Diego,
California).
3 | RESULTS
Out of 11 patients screened, 10 were eligible and randomized in the
study. Nine participants completed both trial arms as one patient
withdrew after the first exercise period for personal reasons. Data for
this participant were not used in the analysis. All included participants
were already on IDeg at least 3 months prior to the start of the study.
Accompanying home physical activity did not differ between the two
dosing schemes as shown by the median (interquartile range) MET of
2499 (2109-7284) min/wk versus 2958 (1358-8360) min/wk
(P = 0.84) in the 100% IDeg and 75% IDeg periods, respectively. The
median (interquartile range) amount of accompanying physical exer-
cise, as documented by the participants, was also not significantly dif-
ferent between the two dosing schemes: 100% IDeg: 30 (8-54)
min/wk versus 75% IDeg: 20 (3-35) min/wk (P = 0.34). Participants
consumed comparable amounts of carbohydrates at their last pre-
exercise meals on each of the 5 exercise days (P = 0.18). The mean
carbohydrate amount at their last pre-exercise meals was also compa-
rable between the dosing schemes (100% IDeg 62  6 g vs. 75% IDeg
64  15 g, respectively; P = 0.83). Absolute recorded time periods
with available glucose readings were similar in both dosing schemes
(P = 0.15), hence we used calculations for absolute and relative time
spent in glycaemic ranges for our analyses.
3.1 | Participant characteristics
The four women and five men completing the present study had a
mean  SD age of 32.1  9.0 years, a mean  SD body mass index
of 25.5  3.8 kg/m2, a mean  SD (min.– max.) HbA1c of 55  7
(43–62) mmol/mol (7.2  0.6 [6.1-7.8]%), a mean  SD (min.– max.)
diabetes duration of 19  10.9 (6-42) years and a mean  SD total
daily insulin dose of 35  13 IU. The mean  SD (min.– max.) maxi-
mum oxygen uptake (VO2max) was 39  12 (22-64) mL/kg/min, maxi-
mum heart rate was 182  13 beats/min, maximum RER was
1.23  0.09, maximum lactate concentration was 11.8  2.2 mmol/L,
power at LTP1 (PLTP1) 57  21 W, power output at LTP2 (PLTP2)
147  47 W and maximum power output (Pmax) 227  77 W. All par-
ticipants achieved the predefined criteria for maximal exhaustion.
3.2 | Physiological and performance data
The 100% IDeg dose corresponded to a mean  SD total daily basal
insulin dose of 19  4 IU while for 75% IDeg it was 14  3 IU. The
mean physiological characteristics over the 5 exercising days were
similar during the 100% IDeg and 75% IDeg dosing periods (Table 1).
3.3 | Glycaemic responses during the 5-day exercise
period
Glycaemic data were compared from immediately post-first exercise
session until 24 hours post-last exercise session for each dosing
period. The 75% IDeg dose resulted in a significant increase in time
spent in euglycaemia (P = 0.04). No significant differences were found
for time spent in hypo- and hyperglycaemic ranges, hypoglycaemic
episodes, glycaemic variation, carbohydrate consumption or insulin
administration, as shown in Table 2 (P > 0.05).
3.4 | Glycaemia at daytime versus night-time during
the 5-day exercise period
While there was a numerical trend for more time spent in euglycaemia
for the 75% IDeg dosing period during night-time, it did not reach sta-
tistical significance (P = 0.059; Table 3):
3.5 | Glycaemia during the first and last phase of the
exercise period
No significant differences for glycaemic ranges were found comparing
the 100% IDeg and 75% IDeg period when analysing data within the
first 48 hours and last 48 hours of the 5-day exercise intervention
(P > 0.05; Table 4).
TABLE 1 Exercise physiological data comparing 100% insulin
degludec (IDeg) and 75% IDeg dosing
100%IDeg 75%IDeg P
VO2 of VO2max, % 62  6 64  7 0.14
VO2, mL/kg/min 23  6 25  6 0.56
Heart rate, beats/min 132  12 135  11 0.06
RER 0.97  0.06 0.96  0.07 0.08
Lactate, mmol/L 2.1  0.1 2.2  0.2 0.78
Abbreviations: IDeg, insulin degludec; RER, respiratory exchange ratio;
VO2, oxygen uptake; VO2 of VO2max, oxygen uptake presented as percent-
age of maximum oxygen uptake.
Values are given as mean  SD and mean difference.
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3.6 | Plasma insulin levels
No significant differences were found for plasma insulin concentra-
tions in the two dosing schemes (P = 0.34). Significant differences
were found within dosing schemes in plasma insulin levels over the
time course (basal insulin dose × time) with a drop during the exercise
and a rise over the next 23 hours (P = 0.002; Figure 1).
TABLE 2 Comparison of the entire 5 days of exercise in the 100% insulin degludec (IDeg) and 75% IDeg dosing period for glycaemic ranges, area
under the curve for hyperglycaemic, euglycaemic, hypoglycaemic ranges, hypoglycaemic events, coefficient of variation for glycaemia,
carbohydrate consumption and insulin administration
Overall 100% IDeg 75% IDeg P
Timeeuglycaemia, min 3566  856 4008  938 0.04
Timeeuglycaemia, % 57  14 62  15 0.16
Timehypoglycaemia, min 240 (128-465) 270 (90-683) 0.07
Timehypoglycaemia, % 3.6 (1.9-7.9) 4.0 (1.3-10) 0.10
Timeserious hypoglycaemia, min 45 (0-105) 30 (0-233) 0.15
Timeserious hypoglycaemia, % 0.7 (0-1.7) 0.4 (0-3.5) 0.30
Timehyperglycaemia, min 2440  1094 2187  1046 0.38
Timehyperglycaemia, % 38  16 33  16 0.23
Timeserious hyperglycaemia, min 195 (0-420) 165 (23-405) 0.36
Timeserious hyperglycaemia, % 2.8 (0-7.3) 2.7 (0.4-5.9) 0.64
AUCeuglycaemia 11 310  3190 12 772  3214 0.08
AUChypoglycaemia 121  106 153  138 0.09
AUCserious hypoglycaemia 107 (0–248) 65 (0–600) 0.30
AUChyperglycaemia 5893  3092 5332  3024 0.52
AUCserious hyperglycaemia 374 (0-1259) 192 (7-846) 0.84
Hypoglycaemic events per participant over 5 days, n 4.7  2.9 4.8  3.4 0.91
CVglycaemia, % 39  7 40  7 0.57
Prandial insulin used, IU 73  40 72  32 0.89
Correction insulin used, IU 17  10 20  10 0.31
Prandial carbohydrates, g 648  115 739  237 0.10
Correction carbohydrates, g 259  114 219  112 0.17
Abbreviations: AUC, area under the curve; CV, coefficient of variation; IDeg, insulin degludec.
TABLE 3 Comparison of 100% insulin degludec (IDeg) and 75% IDeg dosing for glycaemic ranges, hypoglycaemic events, coefficient of variation
and for glycaemia, based on time of day (night-time or daytime)
100% IDeg 75% IDeg P
Night-time (12:00 AM to 6:00 AM)
Timeeuglycaemia, min 695  228 947  350 0.059
Timeeuglycaemia (%) 43  12 54  20 0.10
Timehypoglycaemia, min 105 (8-300) 195 (0-330) 0.39
Timehypoglycaemia (%) 6 (0.5-21) 12 (0-18) 0.64
Timehyperglycaemia, min 755  397 582  379 0.23
Timehyperglycaemia (%) 45  23 33  22 0.17
Hypoglycaemic events (n) (per participant over
5 days)
1 (1-3) 1.7  1.5 0.99
CVglycaemia (%) 39  13 40  11 0.86
Daytime (6:00 AM–12:00 AM)
Timeeuglycaemia, min 2732  686 2739  1342 0.49
Timeeuglycaemia,% 60  14 57  24 0.31
Timehypoglycaemia, min 165 (53-210) 105 (38-405) 0.82
Timehypoglycaemia, % 3 (1.5-5.5) 2 (1.5-9) 0.93
Timehyperglycaemia, min 1677  789 1598  799 0.71
Timehyperglycaemia, % 36  16 38  25 0.75
Hypoglycaemic events (n) 4  2.5 2 (1.5–6) 0.44
CVglycaemia, % 38  6 38  7 0.95
Abbreviations: CV, coefficient of variation; IDeg, insulin degludec.
Values are given as mean  SD or median (25-75 percentile).
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4 | DISCUSSION
The present study showed that a reduction in IDeg dose in people
with T1D while performing regular exercise over 5 consecutive days
improves time spent in euglycaemia significantly. Numerically, albeit
not statistically significantly, 75% IDeg reduced time spent in hyper-
glycaemia. Interestingly, time spent in hypoglycaemia (3.9 mmol/L
[70 mg/dL]) was numerically increased, while time spent below
3 mmol/L (54 mg/dL) was numerically lower under the 75% dosing
scheme.
Although participants administered similar amounts of prandial
insulin for both dosing schemes, the prandial carbohydrate intake was
non-significantly but numerically higher for the 75% IDeg dosing
scheme while the correction carbohydrate intake was numerically
higher during the 100% IDeg dosing scheme. It could be speculated
that participants were more hesitant about having additional correc-
tion carbohydrates as they knew they were on the lower basal insulin
dose; however, given these inconclusive data, the small proportion of
time spent in hypoglycaemia and the fact that none of these findings
were statistically significant, future, larger studies are needed to clarify
the impact of various IDeg doses on hypoglycaemia.
Importantly, the reductions in IDeg dose did not alter bolus insulin
therapy while improving time spent in euglycaemia, which support the
ease of use in regularly exercising people with T1D. A non-significant
difference was observed for heart rate (−3  0.4 b/min) and RER
(−0.01  0.03) when comparing the two dosing schemes, which was
considered biological variability.
The effects of regular exercise training on glycaemic control are
equivocal.25 Exercise may lead to a glycaemic benefit in young people
with T1D when undertaken for longer periods, but this was not found
in adults with T1D. A potential reason for this finding may be a man-
datory increased carbohydrate intake to prevent exercise-induced
hypoglycaemia leading to a mismatch of carbohydrate to insulin ratio.
Reducing the basal insulin dose by 25% might support the beneficial
effects of regular exercise on glycaemic control in individuals with
T1D if additional carbohydrate intake is reduced.
Regular exercise increases insulin sensitivity in both people with
type 1 and those with type 2 diabetes.26,27 The physiological under-
pinning mainly lies in the transcription of glucose transport proteins
(glucose transporter type 4), its movement and insertion into mem-
branes, facilitating insulin-independent intramuscular glucose
uptake.28 While blood glucose homeostasis in healthy individuals is
regulated via increasing counterregulatory hormones and its effect on
hepatic glycogen depletion, glucagon fails to increase in people with
TABLE 4 Comparison of 100% insulin degludec (IDeg) and 75%IDeg for glycaemic ranges, hypoglycaemic events, coefficient of variation
(CV) and for glycaemia based on the first (first 48 h) and last exercise phase (last 48 h)
100% IDeg 75% IDeg P
First phase (first 48 h)
Timeeuglycaemia, min 1560 (1343-2880) 1738  680 0.15
Timeeuglycaemia, % 59 (48-76) 63  11 0.28
Timehypoglycaemia, min 90 (23-390) 60 (23-428) 0.99
Timehypoglycaemia, % 4 (1-8) 2 (1.5-15) 0.87
Timehyperglycaemia, min 953  533 1003  248 0.74
Timehyperglycaemia, % 35  20 34  18 0.66
Hypoglycaemic events, n (per participant per 5 days) 2.1  1.3 2 (1-3.5) 0.67
CVglycaemia, % 37  8 36  6 0.69
Last phase (last 48 h)
Timeeuglycaemia, min 1497  338 1653  479 0.20
Timeeuglycaemia, % 55  13 62  16 0.16
Timehypoglycaemia, min 105 (30-248) 75 (15-188) 0.71
Timehypoglycaemia, % 4 (1-10) 3 (0.5-7) 0.71
Timehyperglycaemia, min 1055  502 783  39 0.13
Timehyperglycaemia, % 38  18 30  15 0.17
Hypoglycaemic events (n) 2.3  1.6 1.9  1.5 0.46
CVglycaemia, % 38  8 41  11 0.53
Abbreviations: CV, coefficient of variation; IDeg, insulin degludec.
Values are given as mean  SD or median (25-75 percentile).
FIGURE 1 Plasma insulin for 100% insulin degludec (IDeg; dotted
line) and 75% IDeg (full line) for immediately before (M1) and
immediately after the first exercise session (M2), 23 hours after the
first exercise session (M3), immediately before (M4) and immediately
after the last exercise session (M5) as well as 23 hours after the last
exercise session (M6). *Indicates significant differences over time for
100% IDeg and 75% IDeg. Values are given as mean  SD
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T1D and thus to prevent exercise-induced hypoglycaemia.7 Further-
more, circulating exogenous insulin levels persist on the basis of its
duration of action,29 which increases the risk of short- and long-term
exercise-induced hypoglycaemia.
Interestingly, neither the time of day (daytime or night-time) nor
the phase within the 5 exercise days (first 48 hours or last 48 hours)
differed significantly when comparing glycaemic ranges, AUC, hypo-
glycaemic events or glycaemic variably for 100% IDeg versus 75%
IDeg. As participants were trained in how to prevent nocturnal hypo-
glycaemia, this potentially had an influence on our results. Training
was needed for safety reasons as participants used an intermittently
viewed CGM system instead of real-time CGM, which does not offer
an automatic hypoglycaemia alarm.
The coefficient of variation in glycaemia was similar when com-
paring dosing schemes for the 5-day exercise period, time of day and
phase within the 5 days (first and last 48 hours), which showed that
IDeg dose reductions around regular exercise were not accompanied
by large glucose fluctuations. Free plasma insulin levels were similar
between 100% IDeg and 75% IDeg, with numerically slightly higher
levels while on 100% IDeg. Similarly to the authors of previous stud-
ies, we observed a drop in plasma insulin levels during exercise.6,30
Most bolus insulins show their peak action ~2 hours after injection,
followed by a decrease in circulating insulin levels through attenuation
of bolus insulin.31,32 In the present study, exercise was performed at
least 2 hours after bolus insulin injection, which might explain the
decrease in plasma insulin levels during exercise, as bolus insulin
action mitigates.
While the present study shows that the time spent in euglycaemia
during multiple moderate exercise sessions is increased with the 75%
IDeg dosing scheme, we have to clearly acknowledge that a number
of findings (eg, time spent in hypoglycaemia, prandial carbohydrate
intake) were approaching but not reaching statistical significance and
should be interpreted with caution. Larger exercise trials in people
with T1D are urgently needed to clarify dose adjustments around
exercise sessions of various types and volumes.
Despite the fact that regular IGlar is associated with more hypo-
glycaemic episodes than basal insulin detemir (IDet; Levemir, Novo
Nordisk) during and after exercise,11 a 20% reduction in both IGlar
and IDet protected against hypoglycaemia for 24 hours after evening
exercise.10 The extended duration of action of IDeg could lead to the
misinterpretation that patients lose flexibility in dose adjustments
around exercise.5 This might hold true for isolated, unregular exercise
bouts, but the present study demonstrates that for participants with
T1D performing exercise over 5 consecutive days, IDeg can be used
but the dose should be reduced by 25%, as has been observed for
other long-acting insulin analogues.
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